Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schaeffer

Showing results (641-650 of 790) with videos related to

Pageof 79
Sort By:
The Prostate|June 20, 2025
Genomic Signatures Correlating With Adverse Pathologic Features in Men Eligible for Active SurveillanceJamie Michael, Eric V Li, Mitch Huang, et al.
BJU International|April 16, 2014
Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk featureFarzana A Faisal, Debasish Sundi, Phillip M Pierorazio, et al.
World Journal of Urology|February 26, 2026
Urologic malignancy risk with chronic tumor necrosis factor-alpha inhibitor (TNF-I) exposure: a multicenter, retrospective cohort studyConor B Driscoll, Jordan M Rich, Christopher Yang, et al.
European Urology|April 30, 2015
Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk MenAshley E Ross, Kasra Yousefi, Elai Davicioni, et al.
The Science of the Total Environment|April 26, 2020
In situ degradation of biodegradable plastic mulch films in compost and agricultural soilsHenry Y Sintim, Andy I Bary, Douglas G Hayes, et al.
Journal of Inflammation (London, England)|August 15, 2025
Long-term risk of de novo malignancy with tumor necrosis factor alpha (TNF) inhibitor immunosuppression: a multicenter, retrospective cohort studyConor B Driscoll, Jordan M Rich, Christopher Yang, et al.
Bioorganic & Medicinal Chemistry Letters|March 26, 1999
Potent, orally bioavailable somatostatin agonists: good absorption achieved by urea backbone cyclizationA Pasternak, Y Pan, D Marino, et al.
Cancer|February 1, 2017
Transcriptome evaluation of the relation between body mass index and prostate cancer outcomesHyun Kim, Ingrid Kalchman, María Santiago-Jiménez, et al.
American Journal of Public Health|March 1, 1971
Report of the committee on professional education, 1970J D Porterfield, S J Axelrod, A G Bridge, et al.
The Prostate|July 11, 2020
Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significanceHarsimar Kaur, Iryna Samarska, Jiayun Lu, et al.
Pageof 79

Showing results (641-650 of 790) with videos related to

Sort By:
Pageof 79
The Prostate|June 20, 2025
Genomic Signatures Correlating With Adverse Pathologic Features in Men Eligible for Active SurveillanceJamie Michael, Eric V Li, Mitch Huang, et al.
BJU International|April 16, 2014
Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk featureFarzana A Faisal, Debasish Sundi, Phillip M Pierorazio, et al.
World Journal of Urology|February 26, 2026
Urologic malignancy risk with chronic tumor necrosis factor-alpha inhibitor (TNF-I) exposure: a multicenter, retrospective cohort studyConor B Driscoll, Jordan M Rich, Christopher Yang, et al.
European Urology|April 30, 2015
Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk MenAshley E Ross, Kasra Yousefi, Elai Davicioni, et al.
The Science of the Total Environment|April 26, 2020
In situ degradation of biodegradable plastic mulch films in compost and agricultural soilsHenry Y Sintim, Andy I Bary, Douglas G Hayes, et al.
Journal of Inflammation (London, England)|August 15, 2025
Long-term risk of de novo malignancy with tumor necrosis factor alpha (TNF) inhibitor immunosuppression: a multicenter, retrospective cohort studyConor B Driscoll, Jordan M Rich, Christopher Yang, et al.
Bioorganic & Medicinal Chemistry Letters|March 26, 1999
Potent, orally bioavailable somatostatin agonists: good absorption achieved by urea backbone cyclizationA Pasternak, Y Pan, D Marino, et al.
Cancer|February 1, 2017
Transcriptome evaluation of the relation between body mass index and prostate cancer outcomesHyun Kim, Ingrid Kalchman, María Santiago-Jiménez, et al.
American Journal of Public Health|March 1, 1971
Report of the committee on professional education, 1970J D Porterfield, S J Axelrod, A G Bridge, et al.
The Prostate|July 11, 2020
Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significanceHarsimar Kaur, Iryna Samarska, Jiayun Lu, et al.
Pageof 79